Bone markers and current laboratory assays

Cancer Treatment Reviews

Volumn 32, Issue SUPPL. 1, 2006, Pages 7-14

  Hannon, Rosernary A ^a   Eastell, Richard ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bone formation; Bone marker assays; Bone resorption; CTX; ICTP; Metastatic bone disease; NTX

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ANTIANDROGEN; AROMATASE INHIBITOR; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K; DEOXYPYRIDINOLINE; HYDROXYLYSINE; HYDROXYPROLINE; MATRIX METALLOPROTEINASE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; PYRIDINOLINE; SIALOPROTEIN; SOMATOMEDIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; BONE REMODELING; BONE SCINTISCANNING; BONE TURNOVER; BREAST CANCER; CANCER SURVIVAL; CELL ACTIVITY; DIAGNOSTIC VALUE; DISEASE COURSE; HUMAN; INDIVIDUALIZATION; INTERMETHOD COMPARISON; LABORATORY TEST; LUNG CANCER; METASTASIS POTENTIAL; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT MONITORING; PREDICTION; PROSTATE CANCER; PROTEIN SECRETION; PROTEIN SYNTHESIS; TREATMENT OUTCOME;

BONE NEOPLASMS; CLINICAL LABORATORY TECHNIQUES; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 33646237342     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(06)80003-4     Document Type: Article

References (79)

1. Mundy G. Metastasis to bone: causes, consequences and therapeutic opportunities. Natl Rey Concer 2 (2002) 584-593
2. Yoneda T., and Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328 (2004) 679-687
3. Clines G., and Guise T. Mechanisms and treatment for bone metastases. Clin Adv Hematol Oncol 2 (2004) 295-301
4. Yin J., Mohammad K., Kakonen S., et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 100 (2003) 10954-10959
5. Mundy G. Endothelin-1 and osteoblastic metastasis. Proc Natl Acad Sci USA 100 (2003) 10588-10599
6. Chen Z., Maricic M., Pettinger M., et al. Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. Cancer 104 (2005) 1520-1530
7. Diamond T., Higano C., Smith M., Guise T., and Singer F. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 100 (2004) 892-899
8. Epub 2005 Sep 27. Greenspan S., Coates P., Sereika S., Nelson J., Trump D., and Resnick N. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90 (2005) 6410-6417
9. Smith I., and Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 348 (2003) 2431-2442
10. Geisler J., Haynes B., Anker G., Dowsett M., and Lonning P. Influence of letrozole and anastrozole on total body aronatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20 (2002) 751-757
11. Eastell R., Hannon R., Cuzick J., Clack G., and Adams J. Effect of anastrozole bone density and bone turnover: results of the 'Arimidex' (Anastrozole), Tamoxifen, Alone or in Combination (ATAC) study. J Bone Miner Res 17 Suppl 1 (2002) S165
12. Lonning P., Geisler J., Krag L., et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23 (2005) 5126-5137
13. Marttunen M., Hietanen P., Tiitinen A., and Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 83 (1998) 1158-1162
14. Apone S., Lee M., and Eyre D. Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone. Bone 21 (1997) 129-136
15. Naylor K., Jackson B., and Eastell R. The renal clearance of free and peptide-bound deoxypyridinoline: response to pamidronate treatment of Paget's disease. J Bone Miner Res 18 (2003) 658-661
16. Cloos P., Fledelius C., Christgau S., et al. Investigation of bone disease using isomerized and racemized fragments of type I collagen. Calcif Tissue Int 72 (2003) 8-17
17. Garnero P., Buchs N., Zekri J., Rizzoli R., Coleman R., and Delmas P. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82 (2000) 858-864
18. Garnero P., Ferreras M., Karsdal M., et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18 (2003) 859-867
19. Garnero P. Markers of bone turnover in prostate cancer. Cancer Treat Rev 27 (2001) 187-192
20. Garnero P., and Delmas P. An immunoassay for type I collagen alpha 1 helicoidal peptide 620-633, a new marker of bone resorption in osteoporosis. Bone 32 (2003) 20-26
21. Al-Dehaimi A., Blumsohn A., and Eastell R. Serum galactosyl hydroxylysine as a biochemical marker of bone resorption. Clin Chem 45 (1999) 676-681
22. Zhang J., Wang J., Tang J., et al. Bone sialoprotein promotes bone metastasis of a non-bone-seeking clone of human breast cancer cells. Anticancer Res 24 (2004) 1361-1368
23. Alatalo S., Ivaska K., Waguespack S., Econs M., Vaananen H., and Halleen J. Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem 50 (2004) 883-890
24. Saftig P., Hunziker E., Everts V., et al. Functions of cathepsin K in bone resorption: lesson from cathepsin K deficient mice. Adv Exp Med Biol 477 (2000) 293-303
25. Holzer G., Noske H., Lang T., Holzer L., and Willinger U. Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures?. J Lab Clin Med 146 (2005) 13-17
26. Delaisse J., Andersen T., Engsig M., Henriksen K., Troen T., and Blavier L. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc Res Tech 61 (2003) 504-513
27. Voorzanger-Rousselot N., Juillet F., Zimmermann J., et al. Association of 13 serum biochemical markers with bone metastases in women with breast cancer. J Bone Miner Res 20 (2005) S224
28. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 142 (2001) 5050-5055
29. Ivaska K., Hentunen T., Vaaraniemi J., Ylipahkala H., Pettersson K., and Vaananen H. Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J Biol Chem 279 (2004) 18361-18369
30. Qvist P., Munk M., Hoyle N., and Christiansen C. Serum and plasma fragments of C-telopeptides of type I collagen (CTX) are stable during storage at low temperatures for 3 years. Clin Chim Acta 350 (2004) 167-173
31. Alexandersen P., Peris P., Guanabens N., et al. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. J Bone Miner Res 20 (2005) 588-595
32. Rogers A., and Eastell R. Circulating osteoprotegerin (OPG) and receptor activator for NFkB ligand (RANKL): clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90 (2005) 6323-6331
33. Blatt J., Allen M., Baddam S., et al. A miniaturized, selfcontained, single-use, disposable assay device for the quantitative determination of the bone resorption marker, NTx, in urine. Clin Chem 44 (1998) 2051-2052
34. Hannon R., and Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 22 Suppl 6 (2000) S30-S44
35. Schlemmer A., Hassager C., Jensen S., and Christiansen C. Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab 74 (1992) 476-480
36. Clowes J., Hannon R., Yap T., Hoyle N., Blumsohn A., and Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30 (2002) 886-890
37. Hannon R., Clowes J., Eagleton A., Al Hadari A., Eastell R., and Blumsohn A. Clinical performance of immunoreactive tartrateresistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 34 (2004) 187-194
38. Seibel M. Clinical use of markers of bone turnover in metastatic bone disease. Natl Clin Pract Oncol 2 (2005) 504-517
39. Ulrich U., Rhiem K., Schmolling J., et al. Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer. Arch Gynecol Obstet 264 (2001) 186-190
40. Jung K., Lein M., Stephan C., et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111 (2004) 783-791
41. de la Piedra C., Castro-Errecaborde N., Traba M., et al. Bone remodeling markers in the detection of bone metastases in prostate cancer. Clin Chim Acta 331 (2003) 45-53
42. Abildgaard N., Brixen K., Kristensen J., Eriksen E., Nielsen J., and Heickendorff L. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 120 (2003) 235-242
43. Terpos E., Politou M., and Rahemtulla A. The role of markers of bone remodeling in multiple myeloma. Blood Rev 19 (2005) 125-142
44. Okabe R., Inaba M., Nakatsuka K., et al. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy: comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline. J Bone Miner Metab 22 (2004) 127-131
45. Koizumi M., Yonese J., Fukui I., and Ogata E. The serum level of the aminoterminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 87 (2001) 348-351
46. Abildgaard N., Bentzen S., Nielsen J., and Heickendorff L. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG). Br J Haematol 96 (1997) 103-110
47. Nguyen-Pamart M., Caty A., Feutrie M., Fournier C., Gosselin P., and Mazeman E. The diagnostic value of urinary CrossLaps and serum alkaline phosphatase in patients with prostate cancer. Br J Urol 80 (1997) 452-455
48. Cloos P., Lyubimova N., Solberg H., et al. An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone. Clin Lab 50 (2004) 279-289
49. Houze P., Bellik B., Brouet J., Bouro F., and Bousquet B. Comparison of urinary markers for bone resorption in multiple myeloma. Clin Chim Acta 300 (2000) 181-193
50. Lyubimova N., Pashkov M., Tyulyandin S., Gol'dberg V., and Kushlinskii N. Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer. Bull Exp Biol Med 138 (2004) 77-79
51. Koizumi M., Takahashi S., and Ogata E. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 23 (2003) 4095-4099
52. Woitge H., Pecherstorfer M., Horn E., et al. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer 84 (2001) 344-351
53. Delmas P. Biochemical markers of bone turnover in Paget's disease of bone. J Bone Miner Res 14 Suppl 2 (1999) 66-69
54. Alexandrakis M., Passam F., Malliaraki N., Katachanakis C., Kyriakou D., and Margioris A. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients. Clin Chim Acta 325 (2002) 51-57
55. Ebert W., Muley T., Herb K., and Schmidt-Gayk H. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res 24 (2004) 3193-3201
56. Jukkola A., Tahtela R., Tholix E., et al. Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP. Cancer Res 57 (1997) 5517-5520
57. Brown J., Vessella R., Kostenuik P., Dunstan C., Lange P., and Corey E. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 7 (2001) 2977-2983
58. Eaton C., Wells J., Holen I., Croucher P., and Hamdy F. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate 59 (2004) 304-310
59. Holen I., Croucher P., Hamdy F., and Eaton C. Osteoprotegerin (OPG) is a varvival factor for human prostate cancer cells. Cancer Res 62 (2002) 1619-1623
60. Martinetti A., Bajetta E., Ferrari L., et al. Osteoprotegerin and osteopotin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. Endocr Relat Cancer 11 (2004) 771-779
61. Pectasides D., Farmakis D., Nikolaou M., et al. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer. J Pharm Biomed Anal 37 (2005) 171-176
62. Kiuchi K., Ishikawa T., Hamaguchi Y., et al. Cross-linked collagen C- and N-telopeptides for an early diagnosis of bone metastasis from breast cancer. Oncol Rep 9 (2002) 595-598
63. Aruga A., Koizumi M., Hotta R., Takahashi S., and Ogata E. Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer 76 (1997) 760-764
64. Shimozuma K., Sonoo H., Fukunaga M., Ichihara K., Aoyama T., and Tanaka K. Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report. Jpn J Clin Oncol 29 (1999) 16-22
65. Diaz-Martin M., Traba M., de la Piedra C., Guerrero R., Mendez-Davila C., and de la Pena E. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma. Scand J Clin Lab Invest 59 (1999) 125-132
66. Lorente J., Valenzuela H., Morote J., and Gelabert A. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Eur J Nucl Med 26 (1999) 625-632
67. Brown J., Cook R., Major P., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97 (2005) 59-69
68. Berruti A., Dogliotti L., Bitossi R., et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 164 (2000) 1248-1253
69. Jukkola A., Bloigu R., Holli K., et al. Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer. Anticancer Res 21 (2001) 2873-2876
70. Keskikuru R., Bloigu R., Risteli J., Kataja V., and Jukkola A. Elevated preoperative serum ICTP is a prognostic factor for overall and disease-free survival in breast cancer. Oncol Rep 9 (2002) 1323-1327
71. Samani K., Brazier M., Mathiot C., et al. Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma. Ann Hematol 84 (2005) 19-24
72. Coleman R., Major P., Lipton A., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23 (2005) 4925-4935
73. Costa L., Demers L., Gouveia-Oliveira A., et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20 (2002) 850-856
74. Noguchi M., Yahara J., and Noda S. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology 61 (2003) 993-998
75. Clezardin P., Ebetino F., and Fournier P. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 65 (2005) 4971-4974
76. Berruti A., Dogliotti L., Tucci M., et al. Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases. Int J Biol Markers 17 (2002) 244-252
77. Pectasides D., Nikolaou M., Farmakis D., et al. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid. Anticancer Res 25 (2005) 1457-1463
78. Luftner D., Richter A., Geppert R., Wernecke K., and Possinger K. Normalisation of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancer. Anticancer Res 23 (2003) 1017-1026
79. Menssen H., Sakalova A., Fontana A., et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20 (2002) 2353-2359